Nxera Pharma Past Earnings Performance
Past criteria checks 0/6
Nxera Pharma's earnings have been declining at an average annual rate of -63.9%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 22.4% per year.
Key information
-63.9%
Earnings growth rate
-62.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 3.4% |
| Revenue growth rate | 22.4% |
| Return on equity | -5.5% |
| Net Margin | -12.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Nxera Pharma Co., Ltd. (TSE:4565) Stocks Pounded By 25% But Not Lagging Industry On Growth Or Pricing
Sep 25
Nxera Pharma Co., Ltd.'s (TSE:4565) P/S Still Appears To Be Reasonable
Jun 26Is Nxera Pharma (TSE:4565) A Risky Investment?
Apr 06Sosei Group Corporation (TSE:4565) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable
Mar 08Revenue & Expenses Breakdown
How Nxera Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 29,275 | -3,711 | 14,407 | 11,579 |
| 30 Jun 24 | 23,340 | -9,836 | 13,618 | 11,523 |
| 31 Mar 24 | 16,434 | -9,072 | 10,708 | 11,281 |
| 31 Dec 23 | 12,766 | -7,193 | 8,167 | 10,075 |
| 30 Sep 23 | 12,402 | -3,378 | 6,377 | 8,844 |
| 30 Jun 23 | 15,258 | 1,860 | 3,841 | 7,795 |
| 31 Mar 23 | 15,393 | 1,050 | 3,290 | 7,607 |
| 31 Dec 22 | 15,569 | 382 | 3,535 | 7,454 |
| 30 Sep 22 | 22,763 | -383 | 3,420 | 7,222 |
| 30 Jun 22 | 17,046 | -224 | 3,469 | 7,031 |
| 31 Mar 22 | 17,624 | 100 | 3,517 | 6,528 |
| 31 Dec 21 | 17,712 | 1,017 | 3,138 | 5,931 |
| 30 Sep 21 | 7,989 | 1,296 | 2,938 | 5,429 |
| 30 Jun 21 | 9,449 | 1,299 | 2,798 | 4,701 |
| 31 Mar 21 | 8,887 | 1,072 | 2,717 | 4,332 |
| 31 Dec 20 | 8,842 | 1,479 | 2,525 | 3,793 |
| 30 Sep 20 | 6,399 | -1,671 | 2,374 | 3,836 |
| 30 Jun 20 | 7,186 | -1,080 | 2,299 | 3,944 |
| 31 Mar 20 | 7,752 | -332 | 2,490 | 3,936 |
| 31 Dec 19 | 9,726 | 1,432 | 2,548 | 4,292 |
| 31 Dec 18 | 3,550 | -6,918 | 2,387 | 6,863 |
| 30 Sep 18 | 3,444 | -5,483 | 2,981 | 6,893 |
| 30 Jun 18 | 5,005 | -4,202 | 3,366 | 5,690 |
| 31 Mar 18 | 6,955 | -2,654 | 3,569 | 4,935 |
| 31 Dec 17 | 8,060 | -2,608 | 3,206 | 4,346 |
| 30 Sep 17 | 8,376 | -1,338 | 2,755 | 3,782 |
| 30 Jun 17 | 6,603 | -1,547 | 2,518 | 3,388 |
| 31 Mar 17 | 18,901 | 9,311 | 2,746 | 3,218 |
| 31 Dec 16 | 17,528 | 6,481 | 3,625 | 3,507 |
| 30 Sep 16 | 21,450 | 9,514 | 3,527 | 3,677 |
| 30 Jun 16 | 22,658 | 10,508 | 3,192 | 3,971 |
| 31 Mar 16 | 8,151 | -1,432 | 2,482 | 3,916 |
| 31 Dec 15 | 10,461 | 2,599 | 2,882 | 3,072 |
| 30 Sep 15 | 5,646 | -255 | 2,499 | 2,313 |
| 30 Jun 15 | 4,010 | -118 | 2,259 | 1,362 |
| 31 Mar 15 | 3,671 | 568 | 1,940 | 557 |
| 31 Dec 14 | 1,169 | 2,191 | -598 | 527 |
| 30 Sep 14 | 1,051 | 1,593 | 935 | 220 |
| 30 Jun 14 | 2,236 | 2,030 | 396 | 375 |
| 31 Mar 14 | 2,069 | 1,526 | 880 | 305 |
| 31 Dec 13 | 1,948 | -849 | 1,825 | 205 |
Quality Earnings: 4565 is currently unprofitable.
Growing Profit Margin: 4565 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4565 is unprofitable, and losses have increased over the past 5 years at a rate of 63.9% per year.
Accelerating Growth: Unable to compare 4565's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4565 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).
Return on Equity
High ROE: 4565 has a negative Return on Equity (-5.48%), as it is currently unprofitable.